Payment overview · 2025
General Payments
$79.21
4 reported records · 4 companies
Healthcare provider profile · identity verified
Vladimir Koren, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FALMOUTH, MA · NPI 1124093950
Verified facts
What the public records show
CMS Open Payments records show Vladimir Koren, MD received $79.21 in general payments during 2025 across 4 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 29.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 310 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 310 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $23.47 | 29.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.72 | 26.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.23 | 23.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.79 | 21.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $79.21 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $20.72 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.79 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 310 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
310 | 47 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
310 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 463 | 138 |
| Levothyroxine Sodium | Levothyroxine Sodium | 444 | 93 |
| Lisinopril | Lisinopril | 327 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 313 | 114 |
| Furosemide | Furosemide | 313 | 72 |
| Eliquis | Apixaban | 310 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 242 | 68 |
| Losartan Potassium | Losartan Potassium | 223 | 74 |
| Gabapentin | Gabapentin | 208 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 207 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 171 | 59 |
| Sertraline Hcl | Sertraline Hcl | 170 | 42 |
| Trazodone Hcl | Trazodone Hcl | 142 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 134 | 38 |
| Indapamide | Indapamide | 131 | 53 |
| Simvastatin | Simvastatin | 121 | 33 |
| Prednisone | Prednisone | 119 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 113 | 33 |
| Omeprazole | Omeprazole | 107 | 43 |
| Metformin Hcl | Metformin Hcl | 105 | 34 |
| Donepezil Hcl | Donepezil Hcl | 102 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 23 |
| Jardiance | Empagliflozin | 99 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 21 |
| Mirtazapine | Mirtazapine | 88 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 46 |
| Potassium Chloride | Potassium Chloride | 81 | 21 |
| Nifedipine Er | Nifedipine | 80 | 22 |
| Latanoprost | Latanoprost | 78 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 24 |
| Atenolol | Atenolol | 66 | 18 |
| Glipizide Er | Glipizide | 65 | 23 |
| Allopurinol | Allopurinol | 63 | 21 |
| Memantine Hcl | Memantine Hcl | 56 | suppressed |
| Mounjaro | Tirzepatide | 56 | suppressed |
| Irbesartan | Irbesartan | 52 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 49 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 45 | suppressed |
| Ezetimibe | Ezetimibe | 44 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | 15 |
| Cephalexin | Cephalexin | 39 | 17 |
| Brimonidine Tartrate | Brimonidine Tartrate | 38 | suppressed |
| Torsemide | Torsemide | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 23 |
| Alendronate Sodium | Alendronate Sodium | 36 | 13 |
| Carvedilol | Carvedilol | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 11 |
| Divalproex Sodium | Divalproex Sodium | 36 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 21 |
| Methenamine Hippurate | Methenamine Hippurate | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | 13 |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Spironolactone | Spironolactone | 28 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 28 | suppressed |
| Valsartan | Valsartan | 27 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | 14 |
| Famotidine | Famotidine | 26 | 12 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 25 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 25 | suppressed |
| Novolog Flexpen | Insulin Aspart | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Timolol Maleate | Timolol Maleate | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 12 |
| Amoxicillin | Amoxicillin | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | 16 |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Klor-Con 10 | Potassium Chloride | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Budesonide | Budesonide | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Multaq | Dronedarone Hcl | 17 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Rivastigmine | Rivastigmine | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | 11 |
| Cefdinir | Cefdinir | 13 | suppressed |
| Ertapenem | Ertapenem Sodium | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $79.21 · 4 records | E.R. Squibb & Sons, L.L.C. | CAMZYOS, ELIQUIS, Wegovy, ZERBAXA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error